您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8065 处方药 7688 非处方药 261 保健品/医疗用具 116

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 心血管系统药物->抗高血压药物
处方药:处方药
包装规格: 40毫克/片 100片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
武田
生产厂家英文名:
TAKEDA
该药品相关信息网址1:
http://www.takeda.com/press/article_46220.html
该药品相关信息网址2:
http://www.info.pmda.go.jp/go/pack/2149048F1022_1_01/2149048F1022_1_01?view=body
原产地英文商品名:
Azilva (アジルバ) 40mg/tab 100tabs/box
原产地英文药品名:
AZILSARTAN
原产地英文化合物名称:
2-Ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid
中文参考商品译名:
AZILVA(アジルバ) 40毫克/片 100片/盒
中文参考药品译名:
阿齐沙坦
中文参考化合物名称:
2-乙氧基-1-[[2'-(4,5-二氢-5-氧代-1,2,4-恶二唑-3-基)联苯-4-基]甲基]苯并咪唑-7-羧酸
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Hypertension
临床试验期:
完成
中文适应病症参考翻译1:
高血压
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20126401304317.PDF,20126401293215.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------
 部分中文Gelclair处方资料(仅供参考)

药名:Edarbi (阿齐沙坦酯azilsartan medoxomil)

适应症:高血压

公司:武田制药(Takeda Pharmaceutical)

类型:小分子药物

简介:Edarbi是每日一次的口服高血压药物。在Edarbi获得FDA批准后,去年冬天,武田制药又一次从FDA获得了好消息。FDA称,研究显示,该药物相对于诺华的代文(Diovan)和第一三共的Benicar,疗效更好。最近,该药在日本和欧洲也获得了批准。在日本以Azilva的商品名出售。

中文名称: 阿齐沙坦

中文同义词: 2-乙氧基-1-[[2'-(4,5-二氢-5-氧代-1,2,4-恶二唑-3-基)联苯-4-基]甲基]苯并咪唑-7-羧酸;阿齐沙坦

英文名称: Azilsartan

英文同义词: AZILSARTAN;2-Ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid;Tak 536;Unii-F9nux55p23

AZILVA® Now Available for a Treatment of Hypertension in Japan
Osaka, Japan, May 28 2012 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced today that AZILVA (generic name: azilsartan) is now available for the treatment of hypertension in Japan. Discovered by Takeda, azilsartan is an angiotensin II receptor blocker (“ARB”) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Azilva is a once-daily, orally administered single tablet, and the available doses are 20 mg and 40 mg.

There were four phase 3 trials of AZILVA conducted in Japan for submission. One of the four phase 3 trials, was a multi-centre, double-blind study* with 636 patients of grade I and II hypertension to evaluate the efficacy and safety of AZILVA in comparison with Blopress® (generic name: candesartan cilexetil), another ARB discovered and marketed by Takeda in Japan. The trial showed AZILVA was superior to Blopress with statistical significance in lowering the change from baseline in sitting diastolic blood pressure. In addition, AZILVA was also superior to Blopress with statistical significance in lowering the mean diastolic blood pressure and systolic blood pressure in 24 hours, daytime and night time as well as in the early morning time, measured by Ambulatory Blood Pressure Monitoring (ABPM). AZILVA was safe and well tolerated, with the safety profile comparable to Blopress.

Masato Iwasaki, Senior Vice President, Pharmaceutical Marketing Division of Takeda, remarked that “Hypertension is one of the major risk factors for all cardiovascular diseases including cerebrovascular disease and myocardial infarction. According to the Japanese Society of Hypertension’s Guidelines for the Management of Hypertension (JSH 2009), there are about 40 million hypertensive patients in Japan, with about half of that number said to be not receiving satisfactory treatment. In the situation where strict management of blood pressure is required for these patients, we believe that AZILVA, having strong and persistent hypotensive effects, may offer a new therapeutic option. We will continue our earnest efforts to provide drug information for AZILVA that will be more useful for both Japanese patients and medical specialists”.

Takeda launches Azilva for blood pressure in Japan
Takeda Pharmaceutical has launched its once-daily angiotensin II receptor antagonist Azilva as a treatment for high blood pressure in Japan.

Azilva (azilsartan medoxomil) will be made available in two doses - 20mg and 40mg - and will be targeted at patients who struggle to meet their blood pressure targets despite current treatment, according to Takeda.

The company said it expects sales of around 3.5bn yen ($45m) in fiscal 2012, while analysts have predicted that it could achieve sales of $700m or more per year at peak, despite being a later entrant into the crowded angiotensin receptor blocker (ARB) category.

In phase III trials, azilsartan was found to lower blood pressure more effectively than three rival angiotensin II receptor antagonists, namely Novartis' Diovan (valsartan), Takeda's own Blopress (candesartan cilexetil) and Daiichi Sankyo's Benicar/Olmetec (olmesartan).

The key to its success will lie in its superior profile to existing ARBs, and how effectively Takeda can market that message in light of the fact that cheaper, generic alternatives to valsartan and losartan are already available.

"There are about 40m hypertensive patients in Japan, with about half of that number said to be not receiving satisfactory treatment," commented Masato Iwasaki, senior vice president, pharmaceutical marketing at Takeda.

"In the situation where strict management of blood pressure is required for these patients, we believe that Azilva, having strong and persistent hypotensive effects, may offer a new therapeutic option," he added.

The product was launched last year in the US and Europe under the Edarbi brand name, and a line extension formulation called Edarbyclor, which combines azilsartan with the diuretic chlorthalidone, was introduced in the US in April, 2012.

It is the only fixed-dose combination of an ARB and chlorthalidone on the market

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20126401304317.PDF,20126401293215.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2019-1-10
附件:




20126401304317.PDF    

20126401293215.PDF    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com